A collective of expert urologists, medical specialists, and experienced researchers working to change the way the world diagnoses and treats prostate disease
📢 Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience
🔗
@LondonProstate1
@EmbertonMark
@Reddy4Urology
MRI after focal therapy - how should we perform it? How should we interpret it?
A pleasure to host 22 experts from Europe and America on Friday for a hybrid consensus meeting. Lots of excellent discussions had - watch this space! 👀
@AJWLight
Full house for the prostate cancer plenary at
#EAU24
- active surveillance vs focal therapy case discussion
Prof Ahmed argues FOR focal therapy
@LondonProstate1
And that’s it for
#ipmasterclass24
!
A big thank you from the
@IP_London
team to all our speakers, delegates, and industry 🙏
See you in 2025 for the next Imperial Prostate Masterclass jointly held with
@FocalSociety
!
PI-RADS is widely used for MRI assessment post-focal therapy but this is inappropriate - results of a systematic review from
@AJWLight
Watch this space for new post-focal MRI consensus guidance 👀
#EAU23
And that’s a wrap on the
#IPmasterclass22
!
A massive thank you to all of our delegates and faculty - a small fraction of whom are pictured here
Till next time!
The RAPID prostate cancer diagnostic pathway allows 43% of men to avoid a biopsy while preserving good detection of clinically significant cancers and low detection of insignificant cancers
@BJUIjournal
📖
📹
#UrSoMe
🏆 Our next award is the Professor Paul Abel Award for Lifetime Achievement in Prostate Cancer
🏆 We are delighted to award this to Professor Mark Emberton
@ucl
!
Citation by
@LondonProstate1
and presented by
@SageOfLondon1
Richly deserved!
#IPmasterclass22
Congratulations to our ACFs
@AJWLight
&
@NikhilMayor
who won 2nd and 3rd prizes at the
@RSMUrology
Winter Short Papers Meeting yesterday for work on MRI in radiorecurrent prostate cancer and computer-aided diagnosis in screening 🥳
🚨What are our current thoughts on Prostate Ca Screening?
📰Latest study from IP1-Prostagram published in this months
@EurUrolOncol
👏A massive team effort led by
@eldredevans
@LondonProstate1
supported by many outstanding collaborators
🔗Read more at
🎓 Huge congratulations to the brilliant
@Mr_EJB_
on the successful submission of his final PhD thesis (late last year)!
📄 ‘The Doctrine of Marginal Gains in Prostate Cancer; Testing Improvement Philosophy with Multiple Randomised Interventions’
#IP3PROSPECT
Prof. Hashim Ahmed
@LondonProstate1
takes the opposition in the case-based debate session ‘Will PSMA PET supplant multiparametric MRI for prostate cancer detection?’
#EAU23
Congratulations to
@ALDCAbreu
who wins the Dr Subhash Arya Award for Best Prostate Cancer Paper for his prospective multicentre evaluation of patient-reported outcomes after focal therapy 🎉 Presented by Mr Manit Arya 🏆
And closing out day 1 of
#ipmasterclass24
is
@ALDCAbreu
- is MRI-invisible disease important?
He (emphatically) argues YES! And yes, we still need systematic biopsy - some aggressive cancers still lurk in the shadows
No shortage of interest in IP-1 PROSTAGRAM results:
➡️
➡️
➡️
We do encourage also reading the paper in
@JAMAOnc
for full details behind the headlines🔬📜🧐!
The paper is open access & free to read for all!
#AUA23
@AJWLight
round two!
Tumour characteristics of mpMRI detected & undetected lesions in patients w/suspected radioreccurent PCa: an analysis from the FORECAST trial
➡️ MRI may miss >30% of tumours @ quadrant level
➡️ MRI undetected tumours were smaller & of lower grade
We welcome back on stage the formidable
@VickersBiostats
Has the use of MRI actually led to overtreatment?
We’ve adapted the diagnostic pathway but not adapted our downstream treatment protocols
#ipmasterclass24
BREAKING NEWS:
@FocalSociety
will partner with Imperial Prostate to deliver a joint Prostate Masterclass as of 2025. Thank you
@RSanchez_Salas
for the update from North America and we look forward to collaborating!
#ipmasterclass24
Kicking off the Imperial Prostate weekend at
#EAU24
is
@AJWLight
giving an expert guided poster tour of his validation of the PRIMARY system in radiorecurrent prostate cancer 💥
The highly-anticipated Focal Therapy Bulletin begins with a breakdown of the
@Uroweb
guidelines by Prof Daniel Eberli. “Do the trials. We need the data,” but acknowledges the difficulty in RCT recruitment in this area, citing high quality prospective registries.
#ipmasterclass24
🎉 Milestone reached for our
#IP8FLUORESCE
trial 🎉
1️⃣0️⃣0️⃣ patients recruited!
Exceptional effort from the team in just 5 months and looking forward to smashing the finish line soon
Our Chair
@LondonProstate1
giving an entertaining but thought provoking talk - screening in the USA is currently NOT productive
Problems lie with no pre-biopsy MRI, systematic TRUS biopsy, and over treatment of disease
@BJUIjournal
@BAUSurology
@USANZUrology
session at
#AUA23
Huge congratulations to our ACF
@AJWLight
for winning the Best Abstract by a Resident at
#EAU24
for the TARGET international consensus study. New recommendations for MRI after focal therapy. Read the full paper here:
Final day of
#AUA23
!
@Reddy4Urology
presenting on % of men eligible for focal therapy
59% eligible in
#PICTURE
, 48% in
#PROMIS
, 68% in
#RAPID
, and 46% in
#PROSTAGRAM
Across settings, many men eligible for focal therapy and this should be offered as such
Thanks to Dr Arnas Rakauskas for an AWESOME year and for your work as a clinical research fellow in our team - best of luck on your return to
@CHUVLausanne
@LondonProstate1
That’s a Wrap
#EAU22
3 Prospective Trials
2 Multi-centre Registries
Thousands of patients generous enough to join in generating our shared Prostate Research Knowledge
We had a fantastic time and will see you all next year in Milan
#EAU23
!
👏 After a two-year hiatus, we can't wait for
#ipmasterclass22
!
#IRL
#springinlondon
📢 Follow us on Twitter & online @ as we reveal our exciting agenda for 2022!
🐦 Take advantage of early bird registration & receive a 20% discount (valid until 31/12)
It was a pleasure today to welcome international colleagues to Charing Cross to watch focal HIFU and cryotherapy
@LondonProstate1
🌎 15 urology, radiology and nursing colleagues from Europe, America and Asia
@SonablateCorp
@bostonsci
🔎 See you at the
#IPmasterclass22
tomorrow!
Before we start proceedings, a HUGE thank you to Emma Cullen who has almost single handedly organised all of
#IPmasterclass22
A true asset to Imperial Prostate!
@LondonProstate1
Meet our Clinical Champion Taimur Shah. Taimur will work closely with patients and primary care professionals to ensure assessment and investigations for prostate cancer are made in a timely manner. Read about his plan for the diagnostic pathway,
💫 Have you checked out the agenda for the
#ipmasterclass24
?
🚀 Join our world-leading faculty & delegates from around the globe 🌍 for two-days of podium sessions & hands-on training!
🌐
🎉 Congratulations
#IP2ATLANTA
- 3️⃣0️⃣0️⃣ patients recruited!
Open across 🏴🏴 for patients seeking additional treatments to their prostate cancer deposits following a new diagnosis of PCa
🔗
And a Commendation goes to our very own
@AJWLight
for his highly impactful paper in
@EurUrol
: the TARGET recommendations for MRI after focal therapy. Congratulations Alex! 🏅
#ipmasterclass24
Welcome to
#ipmasterclass24
from
@LondonProstate1
- “We are entering the renaissance phase of prostate cancer diagnostics” - what a programme we have for the next 2 days!
Would you go back to your Nokia when you have an iPhone? Or back to Hubble from Webb?
Another excellent talk from
@andreasroder1
urging caution in changing our treatment decisions based on PSMA PET
#ipmasterclass24
Someone buy Prof Røder a new bike!